EUVIMEDEUVIMED entdecken
Crossref

Prevention of appearance of severe Huntington's disease symptoms in the R6/1 mouse model by early administration of 4′,5,7-trihydroxyisoflavone

Lidia Gaffke, Estera Rintz, Magdalena Podlacha, Dorota Myślińska, Grzegorz Węgrzyn iD, Karolina Pierzynowska

Journal of Huntington's Disease · 2026-11 · 15 (4) · 599-614

DOI: 10.1177/18796397261472379 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Huntington's Disease, online erschienen am 25.07.2026. Verfasst von Lidia Gaffke und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, Gdańsk, 80-308, Poland. Hauptthemen laut MEDLINE: Huntington Disease, Genistein. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Narodowe Centrum Nauki.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Recent reports indicated that 4′,5,7-trihydroxyisoflavone (genistein) can improve biochemical disorders and correct behavioral disturbances in cellular and animal models of Huntington's disease (HD), acting thorough stimulation of autophagy-dependent degradation of mutant huntingtin aggregates. Effects in the mouse HD model was tested previously only after appearance of symptoms of HD.

Objective

The aim of this work was to assess the efficacy of genistein in preventing the appearance of symptoms in the R6/1 mouse model of HD, using both males and females.

Methods

A battery of behavioral tests (Rota-rod, elevated-plus maze, Morris water maze, monitoring of movements in actometer) was used, and selected biochemical and hematological parameters were determined in control (wild-type) and R6/1 (HD) mice (males and females) treated with either orally-administered genistein at 150 mg/kg/day or water (control). The treatment was initiated at 7 th week of life (while the first symptoms appear at 14–16 week in this HD model), and was continued until 30 th week.

Results

Administration of genistein resulted in extension of life span and prevention of appearance of HD symptoms in R6/1 mice. The immunological and biochemical parameters were comparable between wild-type and R6/1 mice treated with genistein, whereas the untreated HD animals revealed significant differences relative to controls.

Conclusions

Genistein appeared to be effective in preventing the appearance of severe symptoms of HD in the mouse R6/1 model, indicating that this compound might be considered as a potential anti-HD drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Huntington DiseaseGenisteinAnimalsFemaleDisease Models, AnimalMaleMiceMice, TransgenicMaze LearningMotor Activity

Stichwörter der Autor:innen

Huntington's disease mouse modelbehavioral testsbiochemical and hematological markersgenistein (4′,5,7-trihydroxyisoflavone)

Substanzen

Genistein

Autor:innen und Institutionen

  • Department of Molecular Biology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, Gdańsk, 80-308, Poland.
  • Department of Animal and Human Physiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, Gdańsk, 80-308, Poland.

ORCID-Profile: Grzegorz Węgrzyn

Förderung

  • Narodowe Centrum Nauki

Zitieren

APA

Gaffke, L., Rintz, E., Podlacha, M., Myślińska, D., Węgrzyn, G., & Pierzynowska, K. (2026). Prevention of appearance of severe Huntington's disease symptoms in the R6/1 mouse model by early administration of 4′,5,7-trihydroxyisoflavone. Journal of Huntington's Disease, 15(4), 599-614. https://doi.org/10.1177/18796397261472379

Vancouver

Gaffke L, Rintz E, Podlacha M, Myślińska D, Węgrzyn G, Pierzynowska K. Prevention of appearance of severe Huntington's disease symptoms in the R6/1 mouse model by early administration of 4′,5,7-trihydroxyisoflavone. Journal of Huntington's Disease. 2026;15(4):599-614. doi:10.1177/18796397261472379

BibTeX
@article{Gaffke2026,
  author = {Gaffke, Lidia and Rintz, Estera and Podlacha, Magdalena and Myślińska, Dorota and Węgrzyn, Grzegorz and Pierzynowska, Karolina},
  title = {Prevention of appearance of severe Huntington's disease symptoms in the R6/1 mouse model by early administration of 4′,5,7-trihydroxyisoflavone},
  journal = {Journal of Huntington's Disease},
  year = {2026},
  volume = {15},
  number = {4},
  pages = {599--614},
  doi = {10.1177/18796397261472379}
}
Kostenlos starten →